Leveraging our know-how and R&D approach, we have developed a robust clinical and pre-clinical pipeline through a combination of internally discovered and in-licensed products.
- Internal Discovery
- Global Business Development
- Translational Research
Profound understanding
into fundamental
disease biology and clinical practice
Fully integrated global operation
that well-positions us to capture international business opportunities
Seasoned and top-tier management team
Drug Candidate
Target Mechanism
Indications
Lead
Discovery
Proof of
Mechanism
CMC IND Enabling
Phase I
Phase Ib/II
Phase III/Pivotal1
Commercial Rights
Licensor╱Partner
Cancer
Liver Fibrosis
Rare Disease
Notes
(1) Some indication(s) may not require a Phase II clinical trial prior to beginning pivotal Phase II or III clinical trials.
(2) Phase II registration-directed pivotal trial.
(3) The trial is a MRCT covering clinical sites in the U.S. and South Korea. We also plan to include the clinical site in China in the future.
(4) Current clinical trial(s) conducted only in China, but will be extended into MRCT(s) in pivotal trial(s).
(5) LAE003 has been conducted in several Phase I, Phase II clinical trials in various cancer indications prior to our in-licensing. We plan to repurpose the drug for rare disease indications with partners.
Glossary & abbreviations
PROC: platinum-resistant ovarian cancer mCRPC: metastatic castration-resistant prostate cancer mBC: metastatic breast cancer TNBC: triple negative breast cancer HHT: hereditary hemorrhagic telangiectasia ET: endocrine therapy AI: aromatase inhibitors
As of May 31, 2022
AKT + Chemo
>=2L PROC
Global
AKT + CYP17A
2L-4L mCRPC
Global
AKT + PD-1
PD-1/L1 drug-resistant
solid tumors
Global
AKT + PD-L1
>=2L TNBC
Global
AKT + ER
2L-3L CDK4/6i, ET,
Chemo drug- resistant HR+/Her2- BC
Global
CYP17A/CYP11B2
1L mCRPC/mHSPC
Global
ActRIIA
Cancer
Global
NK/T regulator
Cancer
Global
NK/Ø regulator
Cancer
Global
NK/T regulator
Cancer
Global
NK/T regulator
Cancer
Global
TAA
Cancer
Global
TAA
Cancer
Global
aHSC depletion
Liver Fibrosis
Global
aHSC depletion
Liver Fibrosis
Global
Conditional TGFß blocker
Liver Fibrosis
Global
AKT
HHT/Proteus Syndrome
Global
Notes
(1) Some indication(s) may not require a Phase II clinical trial prior to beginning pivotal Phase II or III clinical trials.
(2) Phase II registration-directed pivotal trial.
(3) The trial is a MRCT covering clinical sites in the U.S. and South Korea. We also plan to include the clinical site in China in the future.
(4) Current clinical trial(s) conducted only in China, but will be extended into MRCT(s) in pivotal trial(s).
(5) LAE003 has been conducted in several Phase I, Phase II clinical trials in various cancer indications prior to our in-licensing. We plan to repurpose the drug for rare disease indications with partners.
Glossary & abbreviations
PROC: platinum-resistant ovarian cancer mCRPC: metastatic castration-resistant prostate cancer mBC: metastatic breast cancer TNBC: triple negative breast cancer HHT: hereditary hemorrhagic telangiectasia ET: endocrine therapy AI: aromatase inhibitors
As of May 31, 2022
Conditions | Interventions | Study Title | Status |
---|---|---|---|
Metastatic Castration-resistant Prostate Cancer |
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib |
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC |
Recruiting |
Platinum-resistant Ovarian Cancer |
Drug: Paclitaxel |
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian |
Recruiting |
Breast Cancer |
Drug: Afuresertib |
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
Not yet recruiting |
In the 1990s, due to his passion for biotechnology, Dr. Xiangju Gu left his homeland to study and work overseas. Later, in order to realize hist dream of developing new drugs in China, he followed his heart and devoted to the wave of pharma innovation in Zhangjiang.
Follow us on Linkedin